Skip to main content

Revelation Biosciences, Inc 10-Q for FY2026 Q3

Revelation Biosciences, Inc. (REVB)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Revelation Biosciences, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Revelation says cash is insufficient, raising substantial going-concern doubt, with $9.1 million available and a $59.1 million deficit as of September 30, 2026; Nasdaq delisting is possible if market value stays below $5 million for 30 consecutive business days. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$3.32M
compared with a net loss of $1.91M a year earlier
Diluted EPS
-$5.92
compared with -$49.51 a year earlier